ScripsAmerica's Pharmaceutical Joint Venture Generates Record Revenue in December
January 06 2014 - 8:30AM
ScripsAmerica Inc. (OTCBB:SCRC) today announced
that the Company received and processed a record high $165,424 in
orders from its pharmaceutical distribution joint venture (JV)
during the month of December.
December's revenue puts ScripsAmerica's JV on a run rate of $2
million and the Company expects to see continued growth as it
begins 2014. Since its formation in August of 2013, revenue
generated from the Company's JV, which provides independent
pharmacies with wholesale prescription drugs, has shown consistent
monthly growth.
ScripsAmerica's CEO, Bob Schneiderman, stated, "The company is
very pleased to close last year with a record setting month for our
pharmaceutical joint venture. Our growth in this business area has
been very impressive with monthly revenue increasing from
approximately $63,000 to over $165,000 in less than two quarters.
ScripsAmerica looks forward to expanding the scope of our wholesale
pharmaceutical distribution operations in 2014 and anticipates
increased shareholder revenue as a result." About
ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and
nutraceutical drugs, delivering pharmaceutical products to a wide
range of end users across the health care industry. End users
include retail pharmacies, hospitals, long-term care facilities and
government and home care agencies. For more information, visit
www.ScripsAmerica.com. Safe Harbor Statement
This release includes forward-looking statements, which are
based on certain assumptions and reflects management's current
expectations. These forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results
or events to differ materially from current expectations. Some of
these factors include: general global economic conditions; general
industry and market conditions, sector changes and growth rates;
uncertainty as to whether our strategies and business plans will
yield the expected benefits; increasing competition; availability
and cost of capital; the ability to identify and develop and
achieve commercial success; the level of expenditures necessary to
maintain and improve the quality of services; changes in the
economy; changes in laws and regulations, including codes and
standards, intellectual property rights, and tax matters; or other
matters not anticipated; our ability to secure and maintain
strategic relationships and distribution agreements. The Company
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: 888-959-7095
ir@sealpointconsulting.com
ScripsAmerica (CE) (USOTC:SCRCQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
ScripsAmerica (CE) (USOTC:SCRCQ)
Historical Stock Chart
From Apr 2023 to Apr 2024